FDA grants RMAT designation to Rocket Pharmaceutical’s therapy for Danon Disease
The US Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to Rocket Pharmaceuticals’ RP-A501, an investigational adeno-associated virus (AAV)-based gene therapy to treat Danon Disease.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.